Enhancing deep-lung delivery of inhaled dry powder

Our proprietary PRINT® technology allows us to produce drug particles of uniform size and shape to potentially improve the safety, efficacy, and performance of a wide range of therapies.

Diagram of human lungs with bronchi. Colored dots represent inhaled dry powder particles ranging from 1 to 5 micrometers in size. Smaller particles (blue, 1-2µm) reach deeper into the lungs than larger particles (red, 5µm) which deposit higher in the airways. Inset image shows magnified view of dry powder particles.

Uniform size and shape

The benefits of uniformly shaped and sized drug particles for inhaled delivery:

  • Targeted delivery to the site of the disease1
    • Drug particles <2 μm have greater likelihood for lower airway deposition and reduced chance of sedimenting in the upper respiratory tract2
    • PRINT drug particles are uniform in size and shape, and engineered for enhanced aerosolization for deep-lung deposition
  • Reduced systemic exposure with the possibility of reduced adverse events1
  • Improved aerodynamic properties1
  • Enhanced stability and storage1
  • Flexibility to produce a broad range of medications1

Has potential applications to any therapeutic area, molecule, and route of delivery

  • Customized duration of drug release
  • Increased drug loading
  • Novel drug combinations
  • Improved storage and stability

References:

  1. Data on file. Liquidia Technologies, Inc.
  2. Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics. 2020;13(1):31. doi:10.3390/pharmaceutics13010031